ACCEPT SIMS AI™ · BloomShield CIC

BloomShield-branded research demonstrator

RESEARCH DEMONSTRATOR — SYNTHETIC DATA ONLY — NOT FOR CLINICAL USE

Synthetic-data research demonstration · Mock mode — simulated responses, no live AI · Not for clinical use.

Integrated demonstration

Synthetic data only · Not for clinical use. Administrative decisions never establish diagnostic completion.

Load EXP-0885 · Site E · 15 November 2026

Load the fixed scenario above to follow the demonstration. Other filters and dates retain their own historical context.

Which intelligence is being demonstrated?
  • Model A: trained referral-time prediction evaluated on synthetic data, with a 60-day horizon and historical-cutoff safeguards.
  • Event-triggered review: deterministic navigation intelligence based on documented events; no new probability.
  • Generative AI: model-generated administrative recommendations in safeguarded Live mode. Mock mode uses a deterministic fixture and makes no model call.
  • Model B: proposed future dynamic prediction, not yet trained or implemented; no probability is available.
Uploads

Planned ingestion capabilities — not yet operational. This demonstration uses a fixed synthetic cohort.

  • Direct entry with mobile-friendly forms and future offline capabilities.
  • Validated CSV/Excel imports with schema, chronology and data-quality checks.
  • Secure integrations with existing records, laboratory and appointment systems, potentially using HL7 FHIR.

Programme dashboard

Screening activity and follow-up across the synthetic programme.

Site
Screening modality

Programme activity

Unique participants screened
3,816
Screening encounters
4,484
Diagnostic referrals
853
Outstanding pathways
308

Screening pathway

  1. Screening4,484Encounters
  2. Positive finding1,547Documented findings
  3. Referral853Diagnostic referrals
  4. Follow-up1,012Diagnostic visits
  5. Outcome545Resolved pathways

Stage totals use different units. Pending pathways: 308. Insufficient observation: 0.

Participant insight

Expanded synthetic participant 0109 · EXP-0109Synthetic · Site D

Full participant history through 2026-11-12, across modalities and pathways.

  1. · Screening · VIA · Initial · Programme entry
  2. · Screening result · VIA · VIA positive · Adequate
  3. · Repeat plan · HPV DNA · Prior VIA positive · Scheduled for 2026-02-03
  4. · Diagnostic referral · EXP-0109-T-R
  5. · Contact attempt · Unsuccessful
  6. · Diagnostic booking · Initial booking
  7. · Contact attempt · Unsuccessful
  8. · Barrier documented · Transport difficulty
  9. · Contact attempt · Reached
  10. · Diagnostic visit · Missed
  11. · Diagnostic booking · Rebooking
  12. · Diagnostic visit · Attended
  13. · Diagnosis · Colposcopy · Biopsy collected
  14. · Diagnosis · Histopathology · High-grade lesion
  15. · Follow-up disposition · Resolved · EXP-0109-T-R
  16. · Treatment · Synthetic precancer treatment
  17. · Surveillance plan · HPV DNA · After treatment · Scheduled for 2026-11-13
  18. · Screening · HPV DNA · Repeat · Prior VIA positive
  19. · Screening result · HPV DNA · HPV not detected · Adequate

Referral-time risk

Pathway status at observation · Resolved

Loading prediction…

Observed day-60 outcome · Unresolved

Screened participants

3816 matching participants. Select a participant to review their timeline and referral-time risk.

ParticipantSite
EXP-0293 · Expanded synthetic participant 0293Site E — Resource-Constrained Navigation Programme
EXP-0297 · Expanded synthetic participant 0297Site A — Urban Referral Hub
EXP-0298 · Expanded synthetic participant 0298Site C — Rural Outreach Programme
EXP-0299 · Expanded synthetic participant 0299Site B — Peri-Urban Access Programme
EXP-0300 · Expanded synthetic participant 0300Site A — Urban Referral Hub
EXP-0301 · Expanded synthetic participant 0301Site D — Community Engagement Programme
EXP-0302 · Expanded synthetic participant 0302Site D — Community Engagement Programme
EXP-0303 · Expanded synthetic participant 0303Site D — Community Engagement Programme
EXP-0304 · Expanded synthetic participant 0304Site B — Peri-Urban Access Programme
EXP-0307 · Expanded synthetic participant 0307Site A — Urban Referral Hub
EXP-0308 · Expanded synthetic participant 0308Site E — Resource-Constrained Navigation Programme
EXP-0311 · Expanded synthetic participant 0311Site E — Resource-Constrained Navigation Programme
EXP-0312 · Expanded synthetic participant 0312Site D — Community Engagement Programme
EXP-0313 · Expanded synthetic participant 0313Site A — Urban Referral Hub
EXP-0315 · Expanded synthetic participant 0315Site B — Peri-Urban Access Programme
EXP-0316 · Expanded synthetic participant 0316Site D — Community Engagement Programme
EXP-0317 · Expanded synthetic participant 0317Site D — Community Engagement Programme
EXP-0318 · Expanded synthetic participant 0318Site B — Peri-Urban Access Programme
EXP-0319 · Expanded synthetic participant 0319Site C — Rural Outreach Programme
EXP-0322 · Expanded synthetic participant 0322Site B — Peri-Urban Access Programme
EXP-0323 · Expanded synthetic participant 0323Site B — Peri-Urban Access Programme
EXP-0324 · Expanded synthetic participant 0324Site A — Urban Referral Hub
EXP-0325 · Expanded synthetic participant 0325Site A — Urban Referral Hub
EXP-0326 · Expanded synthetic participant 0326Site D — Community Engagement Programme
EXP-0327 · Expanded synthetic participant 0327Site E — Resource-Constrained Navigation Programme

Programme insights

Encounters by modality

VIA
1722
HPV DNA
2132
Cytology
630

Navigation activity

Barrier documented
760
Contact attempt
1255
Navigation intervention
326
Diagnostic booking
1064
Diagnostic visit
1012

Documented barriers

Contact difficulty
246
Transport difficulty
250
Appointment coordination
264

Site and modality select screening encounters. Pathway status limits the screened group to participants with a matching referral. Referral, navigation and barrier totals count events linked to matching pathways.